Join to access to all OVN content. Join for Free
The Power of Non Traditional KOL Engagement
Nontraditional KOL engagement Medical Science Liaisons strategies personalized communication in healthcare compliance in KOL interactions empathy in healthcare relationships

The Power of Non Traditional KOL Engagement


Share This Article


Summary

In this episode, Tom Caravela is joined by Lindsey Harrer to discuss the power of non traditional Key Opinion Leader (KOL) engagement for Medical Science Liaisons (MSLs). They explore the differences in KOL interactions, strategies for aligning MSL objectives with KOL needs, and the importance of personalized communication. The conversation highlights compliance challenges in nontraditional KOL engagement and its future potential. Lindsey shares insights on applying nontraditional approaches in interviews and MSL strategies, emphasizing the importance of empathy in connecting with healthcare professionals on a human level. The episode concludes with closing remarks and expressions of gratitude.

Key Points

  • Nontraditional KOL engagement focuses on understanding healthcare providers' challenges and needs from a deeply human perspective.
  • Genuine curiosity and active listening are essential in building meaningful relationships and creating tailored solutions for healthcare providers.
  • Partnering with compliance and legal teams from the outset ensures innovative initiatives are implemented effectively and within regulatory guidelines.

Click for Source
Nontraditional KOL engagement, Medical Science Liaisons strategies, personalized communication in healthcare, compliance in KOL interactions, empathy in healthcare relationships

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN